Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

Rituximab in rheumatoid arthritis and the risk of malignancies: Report from a French cohort

(2011) Samy Slimani et al.   JOINT BONE SPINE

Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

(2010) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

(2010) P. P. Tak et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

(2010) J.-E. Gottenberg et al.   ARTHRITIS AND RHEUMATISM

Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials

(2010) R. F. van VOLLENHOVEN et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial

(2010) P. J. MEASE et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)

(2010) A. Rubbert-Roth et al.   RHEUMATOLOGY

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

(2010) J. B. Galloway et al.   RHEUMATOLOGY

Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis

(2009) R. M. Fleischmann   ARTHRITIS AND RHEUMATISM

Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial

(2009) Clifton O. Bingham et al.   ARTHRITIS AND RHEUMATISM

The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis

(2009) Johan Askling et al.   CURRENT OPINION IN RHEUMATOLOGY

Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study

(2009) R. WESTHOVENS et al.   JOURNAL OF RHEUMATOLOGY

The risk of herpes zoster: another cost of anti-TNF therapy?

(2009) Tim Bongartz et al.   Nature Reviews Rheumatology

Cardiovascular Morbidity and Mortality in Rheumatoid Arthritis

(2008) Sherine E. Gabriel   AMERICAN JOURNAL OF MEDICINE

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

(2008) C Salliot et al.   ANNALS OF THE RHEUMATIC DISEASES

A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis

(2008) Allison L Smitten et al.   ARTHRITIS RESEARCH & THERAPY